Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Paula J, Valentine"'
Autor:
Janet A. Jackson, Simon T. Barry, Sandra R. Brave, Sharon Barnett, Graham Richmond, Lee Cooper, Neil H. James, Neil R. Smith, Jane Kendrew, Stephen R. Wedge, Paula J. Valentine, Taylor Sian Tomiko, Michael D. Walker, Sarah J. Boffey, Sarah Beck, Laurent Francois Andre Hennequin, Lyndsey L. Kilburn, Rosemary Chester, Peter F. Wadsworth, Alison L. Bigley, Juliane M. Jürgensmeier, Donald J. Ogilvie, Jon Curwen, Michael Dukes
Publikováno v:
Cancer research. 65(10)
Inhibition of vascular endothelial growth factor-A (VEGF) signaling is a promising therapeutic approach that aims to stabilize the progression of solid malignancies by abrogating tumor-induced angiogenesis. This may be accomplished by inhibiting the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::563f568f32a8e7381f2c10656b8d5a03
https://pubmed.ncbi.nlm.nih.gov/15899831
https://pubmed.ncbi.nlm.nih.gov/15899831
Autor:
Stephen R, Wedge, Donald J, Ogilvie, Michael, Dukes, Jane, Kendrew, Rosemary, Chester, Janet A, Jackson, Sarah J, Boffey, Paula J, Valentine, Jon O, Curwen, Helen L, Musgrove, George A, Graham, Gareth D, Hughes, Andrew P, Thomas, Elaine S E, Stokes, Brenda, Curry, Graham H P, Richmond, Peter F, Wadsworth, Alison L, Bigley, Laurent F, Hennequin
Publikováno v:
Cancer research. 62(16)
ZD6474 [N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine]is a potent, p.o. active, low molecular weight inhibitor of kinase insert domain-containing receptor [KDR/vascular endothelial growth factor receptor (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::835e9fc4dab4d6cc22a73bfa4df9ab16
https://pubmed.ncbi.nlm.nih.gov/12183421
https://pubmed.ncbi.nlm.nih.gov/12183421
Autor:
Rajesh Odedra, Juliane M. Jürgensmeier, Anderson J. Ryan, Paul D. Smith, Philippa Wood, Stephen R. Wedge, Donald J. Ogilvie, Robert W. Wilkinson, Paula J. Valentine, Armelle Logie, Sharon Barnett, Jane Kendrew, Paul Elvin
Publikováno v:
Cancer Research. 70:1372-1372
Cediranib (RECENTIN™) is a highly potent vascular endothelial growth factor (VEGF) signaling inhibitor of all three VEGF receptors that is suitable for once-daily oral dosing. Cediranib is currently in Phase III development in first-line colorectal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3fa40cb22985d3417e2888463db2616
https://doi.org/10.1158/1538-7445.am10-1372
https://doi.org/10.1158/1538-7445.am10-1372
Autor:
Stephen R. Wedge, Jane Kendrew, S. Barnett, Paula J. Valentine, Laurent Francois Andre Hennequin, Juliane M. Jürgensmeier, Donald J. Ogilvie, Sandra R. Brave
Publikováno v:
European Journal of Cancer Supplements. 2:52
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b93e5f6924fe741a4fcd6ddddba6bdfc
https://doi.org/10.1016/s1359-6349(04)80173-3
https://doi.org/10.1016/s1359-6349(04)80173-3